Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 4
2004 4
2005 11
2006 16
2007 13
2008 25
2009 18
2010 24
2011 36
2012 34
2013 23
2014 28
2015 31
2016 32
2017 20
2018 16
2019 8
2020 5
2021 7
2022 4
2023 3
2024 1
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM; CHAPAS-4 Trial Team. Musiime V, et al. N Engl J Med. 2025 May 15;392(19):1917-1932. doi: 10.1056/NEJMoa2404597. N Engl J Med. 2025. PMID: 40367375 Free PMC article. Clinical Trial.
We hypothesized that TAF-emtricitabine would be noninferior to standard care, that dolutegravir and ritonavir-boosted darunavir would each be superior to ritonavir-boosted lopinavir and atazanavir analyzed in combination, and that ritonavir-boosted atazanavir would …
We hypothesized that TAF-emtricitabine would be noninferior to standard care, that dolutegravir and ritonavir-boosted darunavir would each b …
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, Giordano M. Murphy RL, et al. AIDS. 2003 Dec 5;17(18):2603-14. doi: 10.1097/00002030-200312050-00007. AIDS. 2003. PMID: 14685054 Clinical Trial.
OBJECTIVE: To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-naive patients. DESIGN: Randomization to atazanavir 400 mg or 600 mg once daily; nelfinavir 1250 mg twice a day, plus lamivudine and stavudine. ...Adverse events were simi …
OBJECTIVE: To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-naive patients. DESIGN: Randomization …
Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV.
Kengo A, Resendiz-Galvan JE, Najjemba L, Mugerwa H, De Nicolò A, D'Avolio A, Atoyebi S, Wiesner L, Svensson EM, Waitt C, Denti P. Kengo A, et al. Br J Clin Pharmacol. 2025 Dec;91(12):3471-3481. doi: 10.1002/bcp.70195. Epub 2025 Aug 12. Br J Clin Pharmacol. 2025. PMID: 40796001 Free PMC article. Clinical Trial.
A two-compartment model with an effect-compartment effectively described atazanavir concentrations in plasma and PBMC. Rifampicin increased atazanavir clearance threefold, while decreasing its bioavailability and absorption rate. Doubling dosing frequency of ATV/r l …
A two-compartment model with an effect-compartment effectively described atazanavir concentrations in plasma and PBMC. Rifampicin inc …
Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways.
Arora P, Liu H, Ling J, Hindman JT, Marathe DD. Arora P, et al. J Clin Pharmacol. 2025 Nov;65(11):1420-1432. doi: 10.1002/jcph.70061. Epub 2025 Jun 15. J Clin Pharmacol. 2025. PMID: 40518723 Free PMC article. Clinical Trial.
The pharmacokinetics (PK) and safety of bictegravir (administered alone or as bictegravir/emtricitabine/tenofovir alafenamide fumarate [TAF]) were assessed when co-administered with inducers (rifampin, rifabutin, and rifapentine) or inhibitors (atazanavir cobicistat, dar …
The pharmacokinetics (PK) and safety of bictegravir (administered alone or as bictegravir/emtricitabine/tenofovir alafenamide fumarate [TAF] …
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. Davoudi-Monfared E, et al. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01061-20. doi: 10.1128/AAC.01061-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32661006 Free PMC article. Clinical Trial.
Forty-two patients in the interferon group received IFN beta-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-mug/ml (12 million IU/ml) dose of interferon beta-1a was subcutaneously injected …
Forty-two patients in the interferon group received IFN beta-1a in addition to the national protocol medications (hydroxychloroquine plus lo …
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S; AI424-007 Clinical Trial Group. Sanne I, et al. J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):18-29. doi: 10.1097/00126334-200301010-00004. J Acquir Immune Defic Syndr. 2003. PMID: 12514410 Clinical Trial.
Diarrhea was two to three times more common in the nelfinavir group (61% of subjects) than in the atazanavir groups (23%-30% of subjects, <.0001 versus nelfinavir), and jaundice occurred only in atazanavir-treated subjects (6%, 6%, and 12% in the 200-, 400-, and …
Diarrhea was two to three times more common in the nelfinavir group (61% of subjects) than in the atazanavir groups (23%-30% of subje …
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group. Galli L, et al. J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5. J Antimicrob Chemother. 2016. PMID: 26945711 Clinical Trial.
OBJECTIVES: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. METHODS: MODAt is a p …
OBJECTIVES: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically …
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW. Johnson DH, et al. Pharmacogenet Genomics. 2014 Apr;24(4):195-203. doi: 10.1097/FPC.0000000000000034. Pharmacogenet Genomics. 2014. PMID: 24557078 Free PMC article. Clinical Trial.
BACKGROUND: Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of atazanavir and avoidance of its initial prescription. ...METHODS: Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were characterized in HIV-1- …
BACKGROUND: Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of atazanavir and avoidance of its in …
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team. Mirochnick M, et al. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093. J Acquir Immune Defic Syndr. 2011. PMID: 21283017 Free PMC article. Clinical Trial.
BACKGROUND: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure. ...A dose increase of atazanavir/ri …
BACKGROUND: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovi …
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK; AIDS Clinical Trials Group A5316 Study Team. Haas DW, et al. Pharmacogenet Genomics. 2020 Apr;30(3):45-53. doi: 10.1097/FPC.0000000000000396. Pharmacogenet Genomics. 2020. PMID: 32106141 Free PMC article. Clinical Trial.
OBJECTIVE: In AIDS Clinical Trials Group study A5316, efavirenz lowered plasma concentrations of etonogestrel and ethinyl estradiol, given as a vaginal ring, while atazanavir/ritonavir increased etonogestrel and lowered ethinyl estradiol concentrations. ...METHODS: In A531 …
OBJECTIVE: In AIDS Clinical Trials Group study A5316, efavirenz lowered plasma concentrations of etonogestrel and ethinyl estradiol, given a …
328 results